Pharmapark LLC

China’s Bio-Thera Solutions and Russia’s Pharmapark have added the Chinese firm’s BAT2306 proposed rival to Cosentyx (secukinumab) to an existing biosimilars licensing and supply agreement coverin

Bio-Thera Solutions Ltd. has broadened its relationship with Russia’s Pharmapark while expanding the potential geographic reach of its proposed biosimilar to Janssen’s Stelara (ustekinumab), reachi

Prestige Biopharma has expanded its relationship with Russian biopharma Pharmapark , agreeing exclusive terms for Pharmapark to commercialize in its local market Prestige BioPharma’s biosimilar Avas

South Korea’s biopharma IPO market has begun the year on a positive note with a successful and sizable offering on the main Kospi market by Prestige Biopharma Pte. Ltd. Investors will likely remain